Results from a retrospective study of 1,629 patients with non-Hodgkin lymphoma (NHL) showed that survival at 4 years following allogeneic hematopoietic cell transplantation (HCT) for patients age 65 years and older is comparable ...
Feb 21, 2018
0
3
Around 1,500 people in Denmark are diagnosed with lymphatic cancer each year. A small sub-group (70 to 80 people) develop a rare and aggressive type of lymphatic cancer, known as mantle cell lymphoma (MCL).
Feb 20, 2018
0
3
Acalabrutinib is a second-generation Bruton's tyrosine kinase (BTK) inhibitor, a newer class of drugs shown to improve the survival of patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Researchers ...
Dec 13, 2017
0
1
U.S. regulators have approved a new treatment for people with a rare form of non-Hodgkin lymphoma.
Oct 31, 2017
0
0
Notch is one of the most frequently mutated genes in chronic lymphocytic leukemia (CLL), the most common leukemia in adults in the United States. It is also often mutated in other common B cell tumors, such as mantle cell ...
Oct 23, 2017
0
0
Today some patients suffering with mantle cell lymphoma, a type of blood cancer, can be treated with a pill called Ibrutinib, forgoing conventional chemotherapy. However, many are developing a resistance to this treatment. ...
Jun 14, 2017
0
18
A combination of two targeted agents - one approved by the Food and Drug Administration and one undergoing testing - has demonstrated safety as well as encouraging signs of effectiveness in a phase 1 clinical trial in patients ...
Dec 5, 2016
0
2
(HealthDay)—For patients with mantle cell lymphoma (MCL), deferred therapy seems safe and is an independent predictor of overall survival, according to a study published online May 6 in Cancer.
May 24, 2016
0
0
Ibrutinib is a drug for the treatment of rare diseases. It has been approved for the treatment of adults with chronic lymphocytic leukaemia (CLL) or with relapsed or refractory mantle cell lymphoma (MCL) since 2014, and since ...
May 2, 2016
0
2
Ninety-three percent of pediatric patients (55 of 59) with relapsed/refractory acute lymphoblastic leukemia (ALL) went into remission after receiving an investigational therapy made from their own immune cells, with continuous ...
Dec 7, 2015
0
0
